News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aphton Corporation (APHT) Announces Closing of Commercialization and Manufacturing Agreements for IGN311 With Celltrion, Inc.


11/17/2005 12:01:42 PM

PHILADELPHIA--(BUSINESS WIRE)--Nov. 17, 2005--Aphton Corporation (NASDAQ:APHT) announced the formal completion of two agreements with Celltrion, Inc., South Korea for the licensing and commercialization and the product development and manufacturing of Aphton's clinical product candidate IGN311. IGN311, a humanized monoclonal antibody targeting the Lewis Y antigen, is being developed by Aphton's wholly-owned subsidiary, Igeneon AG, as a potential new therapy for the treatment of cancer. Lewis Y is a tumor-related antigen that is expressed in up to 90% of all epithelial cancers, including breast, colon, gastric, and pancreatic cancers.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES